A carregar...
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience
Ibrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor, which has recently gained approval by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with symptomatic Waldenström macroglobulinemia (WM). Herein, we review...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959643/ https://ncbi.nlm.nih.gov/pubmed/27493708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716654102 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|